Autolus – $173 Million IPO

Reston – July 9, 2018 – Cooley advised Autolus Therapeutics on its $172.5 million initial public offering of 10,147,059 American Depositary Shares, which includes the full exercise of the underwriters’ option to purchase additional shares. Cooley partners Christian Plaza, Darren DeStefano and Brian Leaf led the team advising Autolus. 

Goldman Sachs & Co. and Jefferies acted as joint book-running managers for the offering. Wells Fargo Securities and William Blair & Company acted as lead managers.

London-based Autolus, which now trades on the Nasdaq Global Select Market under the symbol “AUTL,” is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

 
Related Contacts
Christian Plaza Partner, Reston
Darren DeStefano Partner, Reston
Brian Leaf Partner, Reston
Courtney Thorne Associate, Boston
Tom Goodman Associate, London
Edward Dyson Associate, London
Katie Kazem Associate, Reston
Mark Jones Associate, London
Esther Cho Associate, Boston
William DuVal Associate, Reston
Paula Fleckenstein Associate, Reston
Related Practices & Industries

Life Sciences Capital Markets Public Companies